Connect Biopharma’s High-Stakes Bet on a New Respiratory Rescue Drug

SAN DIEGO, CA – August 12, 2026 – In the high-stakes world of biotechnology, a company’s entire trajectory can hinge on a single data readout. For San Diego-based Connect Biopharma, that moment is fast approaching. The company announced today that it has completed enrollment for two pivotal Phase 2 studies of its lead drug, rademikibart, positioning it for a make-or-break data reveal in September. The trials are testing a novel application for a biologic: not just managing chronic respiratory disease, but acting as an emergency intervention during life-threatening acute exacerbations of asthma and COPD.

This impending data release marks a critical inflection point for the clinical-stage company. Positive results could validate a first-in-class therapeutic strategy, unlock a multi-billion-dollar market, and fundamentally change how millions of patients are treated during respiratory crises. Negative results could send the company back to the drawing board.

“During the second quarter, we achieved important milestones with the completion of enrollment in both our Phase 2 Seabreeze STAT asthma and chronic obstructive pulmonary disease (COPD) studies,” said Barry Quart, Pharm.D., CEO of Connect Biopharma, in a statement. “With topline results on track for September 2026, we are approaching a key inflection point with randomized, controlled data of rademikibart in patients experiencing an acute exacerbation.”

A New Strategy for Acute Respiratory Crises

For decades, the emergency room playbook for an acute asthma or COPD attack has been consistent: a barrage of short-acting bronchodilators, systemic corticosteroids, and oxygen. While effective, these treatments come with their own side effects and don't address the underlying inflammation in a targeted way. Biologics have transformed the management of chronic severe asthma, but their role in an acute crisis has remained unexplored territory—until now.

Connect Biopharma is aiming to shatter that paradigm. Rademikibart, a monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα), is designed to block the T helper 2 (Th2) inflammatory pathway, a key driver of disease in a large subset of asthma and COPD patients. By focusing on the acute setting, the company is tackling a significant unmet need. Every year, more than a million patients in the U.S. alone seek emergency care for acute asthma attacks.

The two Phase 2 Seabreeze STAT studies enrolled patients globally who were experiencing an acute exacerbation and had high levels of eosinophils, a marker of Type 2 inflammation. These patients received a single subcutaneous dose of either rademikibart or a placebo on top of standard care. The primary goal is to see if the drug can reduce the rate of treatment failure over the next 28 days. A key secondary endpoint, improvement in lung function, will provide crucial insight into the drug’s immediate impact.

Further underscoring its commitment to this acute-care strategy, the company also initiated an open-label study in August to test an intravenous (IV) formulation of rademikibart. The goal is to establish a bridge from the subcutaneous injection to a rapid IV push, which could offer an even faster onset of action in a hospital setting. Early data has suggested IV administration can improve lung function in as little as 15 minutes.

The Science of Differentiation

The IL-4Rα pathway is not uncharted territory. Sanofi and Regeneron’s blockbuster drug Dupixent (dupilumab) targets the same receptor and has achieved massive success in treating chronic conditions like atopic dermatitis and asthma. However, Connect Biopharma argues that rademikibart is not simply a “me-too” drug. The company’s research suggests its antibody has a differentiated binding mechanism that more completely blocks the inflammatory signals of both IL-4 and IL-13.

This potential for enhanced biological activity could be crucial. For instance, while Dupixent is highly effective, it has been associated with an increase in blood eosinophil counts in some patients. Connect Biopharma’s data, in contrast, has shown that rademikibart appears to reduce these inflammatory cells, which could be a significant clinical advantage.

“They’re not just chasing an existing market; they’re trying to create a new one,” commented one industry analyst. “The focus on acute exacerbations is a bold move. If the data shows a clear benefit in reducing hospitalizations or preventing relapses, it could become a new standard of care. No one else is positioned to do that right now.”

Previous Phase 2b data in chronic asthma provided a promising foundation, showing that rademikibart produced rapid and sustained improvements in lung function. Now, the entire industry is watching to see if that promise can be translated into the chaotic and critical environment of an acute exacerbation.

Navigating the Biotech Gauntlet

Ambitious clinical programs require substantial capital, a constant challenge in the biotech sector. Connect Biopharma's latest financial report shows a net loss of $17.3 million for the second quarter, up from $12.9 million in the same period last year, driven primarily by the escalating costs of its advanced clinical trials. This burn rate is the price of progress.

However, the company appears to be on solid financial footing as it approaches its pivotal data catalyst. The press release noted a cash runway of “at least one year,” but deeper analysis of its filings suggests a more robust position, with sufficient funds to operate into the second half of 2027. This financial cushion is critical, providing the stability needed to analyze the upcoming data and plan the expensive next steps without immediate pressure to raise capital under potentially unfavorable terms.

A key pillar of this financial strategy is its partnership with Simcere Pharmaceutical Group. Connect Biopharma licensed the rights for rademikibart in Greater China to Simcere, a deal that is already paying dividends. The $2.8 million in license and collaboration revenue reported this quarter was primarily from a milestone payment related to Simcere’s regulatory progress in China for atopic dermatitis. This partnership provides non-dilutive funding, access to a massive market without the cost of building local infrastructure, and external validation of the drug's potential. With up to $99 million in remaining milestones plus royalties, the Simcere deal serves as a significant financial backstop.

The Path Forward: Regulation and Commercialization

Should the September data prove positive, Connect Biopharma plans to meet with the U.S. Food and Drug Administration (FDA) in the fourth quarter to map out a Phase 3 program. The novelty of its acute-care indication is a double-edged sword. On one hand, addressing a clear unmet need could open the door to an expedited regulatory pathway. On the other, the FDA will undoubtedly apply intense scrutiny to the safety and efficacy data for a biologic used in an emergency setting.

The company’s focus on a biomarker-defined population (patients with Type 2 inflammation) aligns with the FDA's preference for precision medicine and could streamline the path to approval. If successful, the commercial opportunity is immense. Connect Biopharma projects peak sales could exceed $3 billion for asthma and $2 billion for COPD. The strategy is not just to capture the acute treatment market but to leverage that initial touchpoint to convert patients to long-term chronic therapy, creating a powerful commercial flywheel.

For now, everything hangs in the balance, waiting on the results from the Seabreeze STAT studies. For the company, its investors, and millions of patients who live in fear of their next respiratory attack, September can't come soon enough.